Novolog (NVLG) AI Stock Analysis

• Market Cap: ₪497.59M
• Dividend Yield: 3.05%
• Average Volume (3M): 641.09K
• Price to Earnings (P/E): 41.8
• Beta (1Y): 0.68
• Revenue Growth: 22.79%
• EPS Growth: N/A
• Country: IL
• Employees: 936
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.80
• Shares Outstanding: 510,874,760
• 10 Day Avg. Volume: 285,794
• 30 Day Avg. Volume: 641,093
• PEG Ratio: -1.74
• Price to Book (P/B): 1.80
• Price to Sales (P/S): 0.36
• P/FCF Ratio: -18.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: 94.00 ▼(-25.52% Downside)
• Action: Reiterated Date: 03/28/26
• Date: Action: Reiterated 03/28/26

The score is primarily weighed down by deteriorating financial performance—especially the sharp drop in earnings and the shift to negative operating/free cash flow in 2025. Technicals add further pressure with a strong downtrend and oversold momentum, while valuation is only modestly supported by the ~4% dividend despite a high P/E.

Positive Factors

Balance-sheet resilience

A roughly 0.5x debt-to-equity provides structural financial flexibility versus highly leveraged peers. This lower leverage supports refinancing capacity, cushions shocks from cyclical revenue swings, and preserves room for strategic investment or working-capital support over coming quarters.

Negative Factors

Revenue and earnings decline

A sharp year-over-year revenue drop and collapse in net income signal durable demand or competitive pressure issues. Such declines erode operating leverage, strain margins and can persist if market share or pricing power were lost, making recovery of prior profitability uncertain.

Novolog Business Overview & Revenue Model

Company Description

Novolog (NVLG) is a biotechnology company specializing in the development and commercialization of innovative pharmaceutical products, primarily focusing on treatments for diabetes and other metabolic disorders. The company operates in the healthc...

Read more

Novolog (NVLG) is a biotechnology company specializing in the development and commercialization of innovative pharmaceutical products, primarily focusing on treatments for diabetes and other metabolic disorders. The company operates in the healthc...

Novolog Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.81B	2.02B	1.64B	1.51B	1.26B
Gross Profit	124.09M	180.78M	173.76M	176.15M	148.96M
EBITDA	100.75M	149.39M	130.14M	138.53M	115.92M
Net Income	4.12M	39.54M	-42.00M	47.51M	42.32M
Balance Sheet
Total Assets	2.15B	3.04B	2.79B	2.43B	2.29B
Cash, Cash Equivalents and Short-Term Investments	121.77M	247.60M	232.94M	172.81M	238.71M
Total Debt	183.20M	198.47M	215.18M	212.77M	166.81M
Total Liabilities	1.78B	2.65B	2.39B	1.97B	1.86B
Stockholders Equity	356.85M	368.38M	371.08M	436.00M	424.37M
Cash Flow
Free Cash Flow	-34.22M	99.78M	129.06M	63.16M	52.75M
Operating Cash Flow	-16.50M	158.52M	200.01M	132.65M	83.39M
Investing Cash Flow	-61.92M	-50.55M	-72.60M	-124.95M	-69.07M
Financing Cash Flow	-46.02M	-94.59M	-67.71M	-72.96M	47.49M

Novolog Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 126.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NVLG, the sentiment is Negative. The current price of 126.2 is above the 20-day moving average (MA) of 111.68, above the 50-day MA of 117.43, and below the 200-day MA of 128.82, indicating a bearish trend. The MACD of -5.47 indicates Positive momentum. The RSI at 21.28 is Positive, neither overbought nor oversold. The STOCH value of 25.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:NVLG.

Novolog Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BWAY	76 Outperform	₪1.70B	61.00	10.95%	―	21.13%	251.25%
SOFW	69 Neutral	₪1.35B	51.44	―	―	29.55%	―
DANE	61 Neutral	₪2.61B	23.22	―	2.98%	5.94%	-52.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NVLG	44 Neutral	₪497.59M	41.80	―	3.05%	22.79%	―